Filtered By:
Therapy: Immunotherapy
Vaccination: Hepatitis Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 23 results found since Jan 2013.
Biomaterial-based delivery platforms for transdermal immunotherapy
Biomed Pharmacother. 2023 Jun 27;165:115048. doi: 10.1016/j.biopha.2023.115048. Online ahead of print.ABSTRACTNowadays, immunotherapy is one of the most essential treatments for various diseases and a broad spectrum of disorders are assumed to be treated by altering the function of the immune system. For this reason, immunotherapy has attracted a great deal of attention and numerous studies on different approaches for immunotherapies have been investigated, using multiple biomaterials and carriers, from nanoparticles (NPs) to microneedles (MNs). In this review, the immunotherapy strategies, biomaterials, devices, and disea...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 29, 2023 Category: Drugs & Pharmacology Authors: Mohammad Dahri Nima Beheshtizadeh Nasrin Seyedpour Amin Nakhostin-Ansari Faezeh Aghajani Simin Seyedpour Moein Masjedi Fatemeh Farjadian Reza Maleki Khosro Adibkia Source Type: research
Highlights into historical and current immune interventions for cancer
Int Immunopharmacol. 2023 Feb 27;117:109882. doi: 10.1016/j.intimp.2023.109882. Online ahead of print.ABSTRACTImmunotherapy is an additional pillar when combined with traditional standards of care such as chemotherapy, radiotherapy, and surgery for cancer patients. It has revolutionized cancer treatment and rejuvenated the field of tumor immunology. Several types of immunotherapies, including adoptive cellular therapy (ACT) and checkpoint inhibitors (CPIs), can induce durable clinical responses. However, their efficacies vary, and only subsets of cancer patients benefit from their use. In this review, we address three goal...
Source: International Immunopharmacology - February 27, 2023 Category: Allergy & Immunology Authors: Kathryn Cole Zaid Al-Kadhimi James E Talmadge Source Type: research
A novel multi-epitope vaccine of HPV16 E5E6E7 oncoprotein delivered by HBc VLPs induced efficient prophylactic and therapeutic antitumor immunity in tumor mice model
In this study, the E5aa28-46, E6aa37-57 and E7aa26-57 peptides were selected and linked to form a novel multi-epitopes vaccine (E765m), which was inserted into the major immune dominant region (MIR) of hepatitis B virus core antigen (HBc) to construct a HBc-E765m chimeric virus-like particles (cVLPs). The immunogenicity and immunotherapeutic effect of the cVLPs vaccine was evaluated in immunized mice and a tumor-bearing mouse model. The results showed that HBc-E765m cVLPs elicited high E5-, E6- and E7- specific CTL and serum IgG antibody responses, and also relatively high levels of the cytokines IFN-γ, IL-4 and IL-5. Mor...
Source: Vaccine - November 14, 2022 Category: Allergy & Immunology Authors: Wang Qi Li Qingfeng Zhang Jing Zheng Maolin Zhang Zhihui Du Wangqi Zhu Shanli Chen Jun Jiang Pengfei Zhang Lifang Source Type: research
Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections
CONCLUSION: The herein described preS1-HDAg immunotherapy is shown to be immunogenic and vaccine-induced antibodies are highly effective at preventing HBV and HDV (super)infection both in vitro and in vivo. Our vaccine can complement current and future therapies for the control of chronic HBV and HDV infection.PMID:35977815 | DOI:10.1136/gutjnl-2022-327216
Source: Cancer Control - August 17, 2022 Category: Cancer & Oncology Authors: Rani Burm Panagiota Maravelia Gustaf Ahlen Sandra Ciesek Noelia Caro Perez Anna Pasetto Stephan Urban Freya Van Houtte Lieven Verhoye Heiner Wedemeyer Magnus Johansson Lars Frelin Matti S ällberg Philip Meuleman Source Type: research
Nucleic acid vaccines: A taboo broken and prospect for a hepatitis B virus cure
World J Gastroenterol. 2021 Nov 7;27(41):7005-7013. doi: 10.3748/wjg.v27.i41.7005.ABSTRACTAlthough a prophylactic vaccine is available, hepatitis B virus (HBV) remains a major cause of liver-related morbidity and mortality. Current treatment options are improving clinical outcomes in chronic hepatitis B; however, true functional cure is currently the exception rather than the rule. Nucleic acid vaccines are among the emerging immunotherapies that aim to restore weakened immune function in chronically infected hosts. DNA vaccines in particular have shown promising results in vivo by reducing viral replication, breaking immu...
Source: World Journal of Gastroenterology : WJG - December 10, 2021 Category: Gastroenterology Authors: Efthymios P Tsounis Athanasia Mouzaki Christos Triantos Source Type: research
